Related Experiment Video
Updated: May 17, 2026
09:33
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
Correlation between cognitive function and the association fibers in patients with Alzheimer's disease using
Jing-Zhi Meng1, Li-Wei Guo, Hong Cheng
1Department of Radiology, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province 210029, China.
Summary
Alzheimer's disease (AD) patients show reduced white matter integrity in key tracts, impacting cognitive function. Superior longitudinal fasciculus (SLF) fractional anisotropy (FA) may serve as a biomarker for cognitive decline in AD.
Area of Science:
- Neuroscience
- Radiology
- Gerontology
Background:
- Alzheimer's disease (AD) is characterized by cortical abnormalities and white matter (WM) changes.
- Investigating WM integrity is crucial for understanding AD's impact on cognition.
Purpose of the Study:
- To assess white matter (WM) tract integrity using fractional anisotropy (FA) in Alzheimer's disease (AD) patients.
- To explore the relationship between FA values and cognitive function in AD.
Main Methods:
- Diffusion tensor imaging (DTI) was used to measure FA in the inferior fronto-occipital fasciculus (IFOF) and superior longitudinal fasciculus (SLF).
- Neuropsychological tests (MMSE, MoCA) and CDR scale assessed cognitive function and dementia severity in 12 AD patients and 18 controls.
Main Results:
- AD patients exhibited significantly decreased FA values in bilateral IFOF and SLF, and lower MoCA scores compared to controls.
- No WM abnormalities were detected using conventional MRI (T1/T2-weighted).
- Decreased SLF FA positively correlated with MMSE and MoCA scores, indicating a link between WM integrity and cognitive performance.
Conclusions:
- Microstructural WM connectivity loss plays a role in cognitive decline in Alzheimer's disease (AD).
- FA values in the superior longitudinal fasciculus (SLF) show potential as a clinical marker for cognitive function in AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...